Summary
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to an emerging health challenge known as “long COVID,” also known as PASC, post-acute sequelae of COVID-19, characterized by symptoms that persist beyond the acute phase of infection. While acute COVID-19 has been extensively studied, the molecular and immunological mechanisms underlying long COVID remain poorly understood. This study aims to investigate these mechanisms by examining the presence of the viral nucleocapsid (N) and spike (S) genes, their mRNA expression, associated immunoglobulins (IgG), and immune regulation via IDO-2 activity in blood of individuals suspected of long COVID. Here we show that a unique pattern of test results contributes to a better understanding of the underlying mechanisms of long COVID, ultimately leading to improved diagnostic and therapeutic strategies for this condition. This study focuses on four key objectives: detecting viral or vaccin induced genetic material, quantifying mRNA expression of the N and S genes, profiling immunoglobulin levels, and measuring IDO-2 activity. These objectives aim to differentiate long COVID from other post-infectious conditions and provide insights into prolonged symptoms. The study population comprised 72 participants, 31 of whom were suspected of having long COVID based on defined symptomatology. Viral genetic material was detected in both symptomatic and asymptomatic individuals, Immunoglobulin levels varied, with symptomatic males exhibiting lower anti-Spike IgG levels than females, suggesting possible gender differences in immune response. Logistic regression models revealed that mRNA spike data alone in this small group was insufficient to predict symptoms presence, but the inclusion of immunoglobulins and inflammatory markers significantly improved predictive accuracy.
Overall, this study highlights the complexity of long COVID and suggests that a multi-variable approach, combining mRNA and genomic spike data with inflammatory markers and demographic factors, provides a basis for effective prediction of symptoms, helping refine diagnostic and therapeutic strategies for long COVID
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: JH en TvE have read the journals policy and these authors of this manuscript have the following competing interests: JH owns the commercial company JorClinic. JorClinic funded this research. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Funding Statement
JorClinic BV, Den Haag, Netherlands.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos